Celsion Corporation, a biotechnology drug development company, has appointed Jeffrey Church as vice president and chief financial officer (CFO).
Church brings more than 30 years of experience in financial management to Celsion, the majority of which are as a CFO. Prior to Celsion, he served as CFO for Alba Therapeutics, Novavax, GenVec, and Meridian Medical Technologies. Church has extensive experience in corporate finance, mergers and acquisitions, investor and Wall Street relations, and SEC reporting. He is a certified public accountant (CPA) and earned a BSc in Accounting, Summa Cum Laude from the University of Maryland.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.